Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
IPO Year:
Exchange: AMEX
Website: stereotaxis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $5.00 | Buy | ROTH MKM |
| 7/12/2022 | $6.00 | Buy | Aegis Capital |
| 6/23/2022 | $6.00 | Buy | B. Riley Securities |
| 1/5/2022 | $11.00 | Buy | Craig-Hallum |
| 1/5/2022 | $13.00 | Buy | Loop Capital |
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2024 financial results conference call When:Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or
ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™. "We are thrilled to announce the first firm order for GenesisX from a pioneering European hospital," said David Fischel, Stereotaxis Chairman and CEO. "Establishing the first GenesisX robotic lab is a critical milestone for us as we advance towards full commercial launch. We look forward to demonstrating the performance and reliability of GenesisX in the demanding clinical environment. GenesisX promises to transform the acc
ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company's commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine. Stereotaxis' MAGiC catheter is a robotically-navigated magnetic ablation catheter designed to perform cardiac ablation procedures that treat hea
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis. Oulu University Hospital has significant experience pioneering the use of robotic technologies for the treatment of heart arrhythmias, having treated over 2,000 patients with original versions of the technology. The implementation of the latest Genesis System introduces significant advances in Robotic Magnetic Navigati
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China's National Medical Products Administration (NMPA). The Magbot™ Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in tight conjunction with Stereotaxis' robotic systems, including the recently NMPA-approved Genesis RMN™, and MicroPort EP's Columbus™ 3D EP Mapping System. Magbot™ inco
ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS) and Neusoft Medical Systems Co., Ltd ("Neusoft Medical Systems") today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL. RSNA is the premier annual radiology forum in the world, with over 50,000 attendees from over 150 countries. Neusoft Medical Systems is a global leader in advanced medical imaging solutions, with over 47,000 installed systems that provide high-quality care to patients and healthcare providers
ST. LOUIS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 36th Annual Healthcare Conference. Mr. Fischel will deliver a formal presentation on Stereotaxis' technology and growth strategy on Thursday, December 5, 2024, at 2:00 pm ET. Mr. Fischel will be available for one-on-one meetings that same day. "This is an exciting period for Stereotaxis and we look forward to sharing our progress in realizing an attractive growth strategy," said Mr. Fischel. "We appreciate the opportunity to engage
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, "MicroPort EP"), today announced regulatory approval of the Genesis RMN® System by China's National Medical Products Administration (NMPA). This approval is a significant milestone, making available the latest advances in minimally-invasive robotic technology to physicians and patients in China. MicroPort EP is initiating full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community. Approval of Genesis is a key element in a broader collaboration between Stereotaxis and MicroPort EP which entails the devel
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System. "We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz," said Prof. Pedro Adragão, Cardiac Electrophysiologist at Hospital da Luz. "Robotics allows us to treat patients with effective individualized therapy and the highest focus on safety. We are pleased to offer thi
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
3 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2024 financial results conference call When:Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What: Stereotaxis third quarter 2024 financial results conference call When: Monday, November 11, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024. "We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company," said David Fischel, Chairman and CEO. "Key milestones achieved include successfully obtaining CE mark in Europe and submitting a 510(k) application in the US for GenesisX, substantial progress with regulatory reviews of MAGiC in Europe and the US, and closing the acq
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 second quarter on Monday, August 12, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2024 financial results conference call When:Monday, August 12, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Interna
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2024. "Stereotaxis is driving continued commercial, technological, and strategic progress," said David Fischel, Chairman and CEO. "We are pleased to report revenue growth in the first quarter and an increase in system backlog with two Genesis systems orders since our last call. Our innovation strategy remains key to driving substantial commercial success, and we are making robust progress on multiple fronts in line with previous timelines. The acquisit
ST. LOUIS, May 13, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP (APT), a privately-held Minnesota-based developer of innovative electrophysiology catheters. "Acquiring APT provides Stereotaxis with high-quality catheter development and manufacturing capabilities, and will amplify and accelerate Stereotaxis' efforts to advance the treatment of complex arrhythmias and the adoption of robotics broadly within endovascular surgery," said David Fisch
ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What: Stereotaxis first quarter 2024 financial results conference call When: Monday, May 13, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Internationa
ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2023. "We enter 2024 having made significant progress in realizing our strategic transformation. This is the year in which we expect all the key puzzle pieces to come together, setting us up for breakout growth to follow," said David Fischel, Chairman and CEO. "Our innovation strategy has a strong foundation, and we are pleased with where we stand. Regulatory submissions for our proprietary robotically-navigated ablation catheter hav
ST. LOUIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 fourth quarter and full year ended December 31, 2023 on Monday, March 4, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2023 financial results conference call When:Monday, March 4, 2024, at 4:30 p.m. EST (1:30 p.m. PST) Dial In Number:To access the live call, dial 800-
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
EFFECT - Stereotaxis, Inc. (0001289340) (Filer)
S-3/A - Stereotaxis, Inc. (0001289340) (Filer)
S-8 POS - Stereotaxis, Inc. (0001289340) (Filer)
S-8 - Stereotaxis, Inc. (0001289340) (Filer)
S-3 - Stereotaxis, Inc. (0001289340) (Filer)
D - Stereotaxis, Inc. (0001289340) (Filer)
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
Craig-Hallum initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $11.00
Loop Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $13.00
Piper Sandler initiated coverage of Stereotaxis with a rating of Overweight and set a new price target of $9.00
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)